Geron :
GERN
GERN
Stock Data
$1.41
$0.07 (5.22%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Geron Corp is a biopharmaceutical company focused on developing treatments for blood cancers. Its main project, imetelstat, is a groundbreaking therapy aimed at stopping the spread of cancerous cells in certain blood disorders. This innovative drug is currently in advanced testing stages, showing promise for patients with specific types of myelodysplastic syndromes and myelofibrosis. Founded in 1990 and based in Foster City, California, Geron is at the forefront of research in telomerase inhibition, a novel approach in cancer treatment.
All Geron Articles
78 Articles